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Abstract
Background: Pancreatic cancer is one of the most challenging tumor entities
worldwide, characterized as a highly aggressive disease with dismal overall prognosis
and an incidence rate equaling mortality rate.
Objective: In order to have an up-to-date data on pancreatic cancer incidence and
trend in Nigeria, West Africa, we conducted an epidemiological analytical review of
the pattern, management, and management outcome of pancreatic cancer in Ibadan,
Nigeria.
Methods: We performed a retrospective hospital-based study in which we analyzed
the records of 126 pancreatic cancer patients registered, evaluated, and treated in
the University College Hospital, Ibadan, a major referral tertiary Hospital in the south
western region of Nigeria, West Africa from January 1999 to January 2013.The data
obtained include bio-data, clinical presentation, treatment and outcome that were
analyzed with descriptive statistics using SPSS 22.
Results: During the period of study, 126 patients were diagnosed with pancreatic
cancer, with a mean age of 60.2 years and a male-to-female ratio of 1.52:1; other
parameters such as a medical history of smoking and alcoholism, tumor site,
histological type, as well as the stage of diagnosis were also considered at the time
of the enrolment in the study. Our statistical analyses reported a very significant
correlation between patients who belonged to the age group of 30–45 years and
the advanced stage of diagnosis (based on TNM classification) with P = 0.02.
Conclusion: Pancreatic cancer is increasingly diagnosed in young adults at an
advanced stage in the West African sub-region. Most patients present with advanced
condition only amenable to palliative measures. There are significant challenges in
the area of diagnosis, screening, treatment and research. The role of public health
campaign to educate the populace on the disease and early presentation cannot be
overemphasized.
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1. Introduction
Pancreatic cancer is one of themost challenging tumor entities worldwide, characterized
as a highly aggressive disease with dismal overall prognosis and an incidence rate
equaling mortality rate [1, 2]. Less developed regions have low rates of pancreatic
cancer [2], and it is relatively rare in Africa and Asia [3, 4]. However, despite all the
efforts in the medical research of the disease, it ranks as the fourth deadliest cancer in
the United States after the cancers of the lung, colon, and breast. The Cancer Registry
at the University College Hospital (UCH), Ibadan, indicates that it trails behind primary
carcinoma of the liver, carcinoma of the stomach, and carcinoma of the colon among
gastrointestinal tumors [5]. The incidence rate in the UCH, Ibadan, is 3.8% [5].
In 2013, an estimated 45,220 newly diagnosed cases of pancreatic cancer and
38,460 deaths were expected in the United States [6]. The main reason could be
the difficulty of its diagnosis since no specific cost-effective screening tests can easily
and reliably find early stage pancreatic cancer in people who have no symptoms of the
disease. This means it is often not found until later stages when the cancer can no longer
be removed with surgery and has spread from the pancreas to other parts of the body
[7]. In fact, the Surveillance, Epidemiology, and End Results (SEER) database also shows
that for every 12.2 patients diagnosed per 100,000, 10.9 will die from pancreatic cancer,
despite the best efforts of researchers and clinicians to improve survival outcomes in
patients [8]. The overall five-year survival rate is less than 5% [9–11]. The peak incidence
of pancreatic carcinoma occurs in the seventh decade [12]. There are variations in
incidence in different populations ranging from 2.2 new cases per 100,000 populations
in India, Kuwait, and Singapore to 12.5/100,000 in Sweden [12, 13]. The incidence in
most developed countries is similar to that of the United States [13]. Most research
on pancreatic cancer has come from developed countries. Some of these researches
have indicted some environmental factors in the occurrence of this disease [14, 15].
The environmental factors include cigarette smoking, alcohol consumption, high meat
intake, and occupational exposure to carcinogen like Dichlorodiphenyltrichloroethane
(DDT) and other organochlorine pesticides. Most of these environmental factors are
very prevalent in Africa, especially Nigeria- the world’s largest nation of people of color.
Study from Egypt showed that the incidence of pancreatic cancer is higher in the area
of the country where this environmental factor abound [16, 17]. Numerous reports have
been published by Western countries on this disease entity but only few works have
been done on this area of interest in Nigeria and Africa in general [5, 8–12, 18–24]. The
need to look at local data also becomes very imperative because of the findings of few
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studies that show that African American and economic disadvantage population have
higher incidence of pancreatic cancer [12–14, 18–26].
This study aimed to bring to the fore the hospital incidence, sociodemographic
characteristics and management′s outcome of carcinoma of pancreas at the UCH,
Ibadan, Nigeria. We also discuss the challenges associated with the management of
the disease in low-resource settings like ours that are typical of the health sector in the
sub-Saharan African region.
2. Methods
The study was conducted at the UCH, Ibadan, Nigeria, from January 1999 to January
2013. The hospital is the largest hospital in the south of Sahara and provides services
to both the rural and urban communities in the southwestern Nigeria. The hospital also
serves as the referral tertiary hospital for an estimated population of approximately
20 million people in the southwestern states of Nigeria and neighboring West African
countries.
2.1. Data collection
This was a retrospective cohort study of all patientsmanaged for pancreatic cancer in the
surgical wards of the UCH, Ibadan, Nigeria, between January 1999 and January 2013.
The admission and discharge diagnosis and procedure codes as well as the Cancer
Registry database were obtained from the Central Record of the hospital. The Current
Procedural Terminology (CPT) and the International Classification of Diseases Ten Revi-
sion (ICD-10) codes for “Triple bypass,” “pancreaticoduodenectomy,” and “pancreatic
cancer” were used to identify patients with proven or suspected pancreas neoplasm
undergoing surgery. Manual review of patient records was performed to obtain relevant
data points. The data collected include the sociodemographics, laboratory parameters,
the treatment modalities, as well as the outcome of management.
The diagnosis of pancreatic cancer wasmade using the combination of clinical param-
eters, upper gastrointestinal endoscopy, and radiological findings. Clinical parameters
used included jaundice, upper abdominal mass, upper abdominal pain that radiate to
the back, weight loss, and palpable gall bladder. Radiological parameters included ultra-
sound and/or Computerized Tomography (CT) scan showing pancreatic mass. Upper
gastrointestinal endoscopy was done for most of the patients to rule out the possibility
of gastric cancer. Endoscopic retrograde cholangiopancreatography was not done
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for any of the patients because the facility was not available. All the patients with
conflicting findings which could not be substantiated at surgery were excluded from
the study. Histopathological finding further corroborated the diagnoses for patients
that had surgery or during the postmortem examination. Sixteen (12.7%) patients did not
have histopathology result.
All the data obtained were coded, edited appropriately, and entered into personal
computer. The data were analyzed using the Statistical Packaging for Social Sciences
(SPSS; IBM Corporation; Chicago, IL, USA. August 2011) version 22.0. Simple descriptive
statistics were used. Median and frequencies were calculated based on the numerous
data points. The P-values were provided to indicate statistical significance. P < 0.05 was
regarded as significant. Chi-square tests were used to compare categorical variables
such as sex. Fisher exact test was used where applicable. Student t-test was used to
compare mean age between the groups.
3. Results
The study population was 126 patients diagnosed with cancer of the pancreas but
only 82 patients had histological proof of pancreatic cancer. This accounted for 3.1% of
all malignancies seen and 358/100000 total admissions during the study period. The
median age was 60.2 years with male-to-female ratio of 1.52.
As seen in Table 1, the most common age group affected with pancreatic cancer is
age group 51–60. There were 76 (60%) male and 50 (40%) female with male-to-female
ratio being 1.52:1. Majority of the patients were artisans (39.8%) and farmers (26.4%).
Other patients were either traders or professionals.
The duration of symptoms ranged from 6 weeks to 125 weeks with a median of
25 weeks. None of our patients had a family history of pancreatic cancer. Only 25
(20%) patients had a previous history of diabetic mellitus (DM) before the onset of the
symptoms. The diagnosis of DM was made within one year prior to the commencement
of the symptoms in all 25 patients; 12 and 15 patients had significant history of cigarette
smoking and alcohol intake, respectively. On investigation, 94% of the patients had
elevation of alkaline phosphatase, 40% had elevated aspartate transaminase, 96% had
elevated bilirubin, and 70% had packed cell volume of less than 28 at the time of
presentation.
Only 12 (11%) patients had tumor located in a specified anatomical sub site: 10 in the
head of pancreas and 2 in the tail of the pancreas. Other patients had extensive tumor
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Table 1: Patients’ medical features.
Characteristics No. of Cases Percentage %
















Abdominal pain 120 95
Right hypochondrial pain 113 90
Nausea & vomiting 111 88
Weight loss 107 85
Dark urine 88 70
Pruritus 82 65
Tumor Site
Head of the Pancreas 113 90
Body of the Pancreas 8 6.2
Tail of the Pancreas 5 3.8
involving the head and body of the pancreas. There were liver metastases in 32 (29.1%)
patients at the time of presentation.
Of the 98 (78%) patients who had surgery, 71 (56%) had triple bypass and 27 (22%)
had a double bypass procedure. Two patients with localized tumor of the head of
pancreas had pancreaticoduodenectomy. The two patients with tumor at the pancreatic
tail had resection of the tumor and splenectomy. Eighty-six (88%) of the operated patients
had locally advanced pancreatic mass. These patients had triple bypass to relieve the
obstructive jaundice. Ten patients had biopsy alone of the pancreatic mass or the lymph
node because of the widespread metastasis to the bowel, liver, and other organs in
the peritoneal cavity. Twenty-eight patients had adjuvant chemotherapy. Agents used
include 5-fluorouracil and Adramycin.
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The two patients who had pancreaticoduodenectomy were lost to follow-up after a
year. No recurrence was recorded for the patient with tumor at the tail of pancreas after
five years of follow-up. Median survival for patients that had triple bypass was eight
months. This was statistically significant (p = 0.02). Within three months of presentation,
42 (33.3%) patients with pancreatic cancer died. As shown in Table 2, the factors that
were found to be significant in patients that died within three month of presentation
include elevated transaminases, low serum protein and bicarbonate. Table 3 shows
the various complications from bypass surgery. The most common complication of triple
bypass is bile leak which was seen in two patients.
Table 2: Factors affecting the outcome of managements of patients with pancreatic cancer.
Factors Degree of
Freedom
P-Value 95% Confident Interval





Serum Bilirubin 94 0.442 –33.854–78.623
ALT 94 0.004 12.254–66.732
AST 93 0.0002 11.684–49.271
Alkaline Phosphate 94 0.932 –354.821–197.472
Total Serum Protein 94 0.054 –11.641–782
Serum Potassium 94 0.851 –3446–2378
Serum Sodium 94 0.444 –6.576–4123
Serum Creatinine 94 0.234 –22.678–54.544
Serum Bicarbonate 94 0.022 –5.777–3240
PT 94 0.044 –2.789–1.233
INR 32 0.232
Table 3: Complications associated with methods of triple bypass.
Complications Braun Method Roux-en-Y Method
Bile leak 2 1
Recurrent vomiting 3 0
Prolonged ileus 3 1
Wound infection 2 1
Total 10 3
4. Discussion
All around the globe, significant progress are being made to better understand the
molecular biology of pancreatic cancer which has not significantly impacted on the
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outcome of management. This is because such concerted past efforts, on the conven-
tional treatment approaches, such as surgery, radiation, chemotherapy, or combinations
have yielded very little results. Pancreatic tumors remain deadly and rarely curable [25,
27–29]. In this study, we found that the hospital incidence of pancreatic cancer is 358
per 100,000 hospital admissions that accounts for 3.1% of all cancer cases seen in our
center. For several decades, the incidence of pancreatic cancer has been consistently
higher in the people of color than in the whites in the United States [27, 28, 30].
The present survey is one of the very few surveys that studied the profile of pancreatic
cancer in West Africa in general and Nigeria in particular.
With a sex ratio of 1.52, our investigation confirmed once more that men are more
likely to develop pancreatic cancer than women. These results matched with many
other previous investigations as those of Schiffman et al. [18, 19, 31].
Our results showed that 28% of our patients were cigarette smokers and 22% were
alcoholics. This could represent a risk factor for developing a pancreatic cancer since
several published reports showed that smokers had about a twofold increased risk
compared to nonsmokers [32, 33].
We noticed also that most of our patients complained of jaundice; right hypochondrial
pain and abdominal pain; which proves that pancreatic cancer is a silent disease,
as reported in many other findings that stated that pancreatic cancer symptoms do
not manifest early and initial symptoms are often nonspecific [18, 19, 34]. Concerning
tumors’ location, most of them were located in the head of the pancreas (90%), followed
respectively by cancer of the neck and the tail of the pancreas that represented a tiny
minority. The study of Kalser et al. demonstrated as well that more than two-thirds of
pancreatic cancers occur in the head of the pancreas [18, 35].
Diabetes mellitus was associated and pointed in several investigations as possible
risk factor for pancreatic cancer [18, 33] in concordance with our findings, since 25% of
our studied population presented with type 1 and type 2 of diabetes.
Our survey also demonstrated an increasing frequency of pancreatic cancer with the
advanced age of patients since most of them were aged between 60 and 80 years old,
these results agree with those of Shibata’s et al. who concluded that this could be due
to the dietary habits of the patients [18, 19, 36].
On the other hand, the current investigation confirmed indeed the rarity of pancreatic
cancer in young adults; since only 8% of our population suffered from it, which agrees
with the results of Perez et al. who found that the incidence of identified pancreatic
carcinomas in patients under the age of 30 was only about 0.46/million [37]. The
conclusion for Lüttges et al. was the same, where the incidence of pancreatic ductal
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adenocarcinomas in patients aged 40 years was approximately equal to 0.3% and the
incidence in patients aged 20 years was only about 0.1% [38].
However, despite the low rate of our patients (8%) belonging to that young age group,
35% of them were diagnosed at M1 stage that represented the majority.
Concordant with our results and those of Brand et al. who found that pancreatic
cancer is increasingly diagnosed among young patients at an advanced stage [39],
Berry et al. stated that nearly 50% of patients aged between 16 and 54 with pancreatic
cancer are more likely than those who are older to be diagnosed at a stage when
the disease is incurable, because of poor awareness, misdiagnosis, and care delays
[18, 19, 40].
Some authors confirm that pancreatic cancer is frequently diagnosed at an advanced
stage, possibly because of the tumor biology showing an aggressive behavior and
symptoms, often being non-specific and mainly among the young ones [41]; Gulliford
et al. reported as well that patients with some less common cancers such as pancreatic
cancer were more likely to require three visits or more to their primary care physician
before they were referred to a specialist [42]. What we have to emphasis as well is the
status of Nigeria as a developing country, thus it’s undeniable that inadequate healthcare
facilities, high-priced drugs, lack of cancer diagnostic and therapeutic kits, insufficient
medical check-ups, as well as the low socioeconomic level of Nigerian citizen are all
major factors that may have a direct impact on the survival chances of this fatal disease.
Since most of our patients had pancreatic adenocarcinomas (Table 2) presented
in late stage at the time of diagnosis, their prognosis was very poor – with a one-year
survival rate of 20% and a five-year survival rate of less than 5% – similar to the survey of
Kuvshinoff et al. [43]. The only hope of long-term survival is if curative resection can be
undertaken; however, since pancreatic cancer patients seldom exhibit disease-specific
symptoms until late in the course of the disease, very few patients (< 15–20%) have
resectable disease by the time the diagnosis is made [18, 19, 44, 45]. While complete
surgical resection may lead to long-term survival in approximately 25% of patients, only
15% are actually resectable [43]. It is therefore essential to distinguish all kinds of tumor
from other pancreatic neoplasms particularly adenocarcinoma for which the prognosis
is extremely poor as stated earlier [46]. Surgery for pancreatic cancer is probably the
most demanding and risky operative procedure in abdominal surgery [47]. Nevertheless,
the huge lack of diagnostic facilities and cancer research centers in Nigeria and other
developing countries have a major negative impact on the precision and quality of the
diagnosis.
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Seelig et al. reported that in a young patient with advanced disease, resection may
give a weak but valuable increased survival. In fact, metastatic pancreatic cancer could
become overt when the point of no return has already been reached as it could be
the case in the presence of positive interaortocaval lymph nodes, or metastatic cancer
will be detected during operation despite negative imaging results preoperatively [48].
Picozzi et al. affirmed that despite R0 resection, long-term survival does not exceed
25% even in the most experienced pancreatic centers and may prove that carcinoma
of the pancreas is a systemic disease [49]. At presentation, most of our patients had
advanced disease. Resection rate was about 3% which is very low compared with the
data from developed country where resection rate of as high as 15–20% has been
quoted [14]. The stage of the tumor has been found to be an important predictor of
resectability and death in patients with pancreatic tumor [50]. This is because of the
location of pancreas; early symptoms of pancreatic cancer are so vague and are usually
ignored by most patient. Presentation with advanced stage of the disease may also
be due to poor health-seeking behavior of our patients [18, 19, 51, 52]. Obviously, a
high index of suspicion on the part of health workers is essential for early detection of
pancreatic cancer. Another reason for late presentation in our patients may be due to
aggressive growth behavior of the pancreatic cancer that leads to early dissemination of
the tumor [14, 53]. Various efforts have beenmade on how to diagnose pancreatic cancer
early with little success [54, 55]. Presently, no population screening modality is available
for pancreatic cancer. Moreover, targeted screening is also very difficult for pancreatic
cancer because primary causal factors for this tumor are poorly understood. While effort
is been made along this line, it is worthy to note that endoscopic ultrasonography has
been shown to be a reliable way to detect tumor invasion of visceral vessels and thus
predict unresectability. It also has the potential to be used to diagnose pancreatic cancer
early [18, 19, 55, 56].
In Solanke et al. [20] series, pancreatico-duodenectomy was performed on only 3 out
of 47 patients; 2 with carcinoma of head of pancreas and 1 with disease of the ampulla of
Vater. One died after two months, another after five months, and the third with ampullary
carcinoma was alive and well after ten months. Palliative procedures were carried out on
14 patients and laparotomy alone was performed on 11 patients. The one-year survival
rate of 2% was reported by Solanke et al., which was similar to this study [20]. Only 6 out
of the 36 patients of Ajao et al. [21] had exploratory laparotomy; none had resectable
disease. In Lagos, 10 out of the 20 patients encountered by Olumide et al. [22] had
laparotomy; none was resectable and 7 had palliative operations consisting of bypass
procedures.
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Further improvement of survival can only be achieved by adjuvant treatment [49].
The need for adjuvant therapy in pancreatic cancer cannot be over emphasized.
Even with complete surgical resection, most patients will die of recurrent disease
because of the multifocality of the disease and micrometastasis [57, 58]. Several studies
have shown that the outcome of patients are improved when placed on adjuvant
chemotherapy, radiotherapy, or a combination of the two [14, 18, 19, 58, 59]. Pancreatic
cancer is moderately sensitive to few agents like gemcitabine, capecitabine, cisplatin,
bevacizumab, and cetuximab [15, 18, 19, 60]. Most of these agents are more toxic, rarely
available in our environment or very expensive. One important question that is yet to
find an answer is the reason why pancreatic cancer is resistance to most commonly
available chemotherapy. Radiotherapy facilities are extremely congested; hence, the
facilities are made available to those that will benefit most from the facilities and the
privileged few. This makes the management of patients with pancreatic cancer very
difficult.
Our survey clearly showed that young adults who suffered from pancreatic cancer in
general and cancer of the head of pancreas in particular are unfortunately diagnosed
at a very late stage in South Western Nigeria, when the likelihood of recovery is poor
and patients have no other choice than to accept their ongoing symptoms.
Furthermore, we found that patients with elevated transaminases, low serum sodium,
and reduced total protein indicate that patients had very advanced disease with a
much reduced life expectancy. These may be due to the involvement of the liver in this
condition. These simple parameters can help predict a poorer outcome at presentation.
Further study will be needed to substantiate this finding. For a long time, pancreatic
cancer has been regarded as terminal disease (“captain of death”); hence little attention
is given to the research on the disease. Report on pancreatic cancer is extremely scarce
in Nigeria or Africa. There is a great need therefore for concerted effort to characterize
pancreatic cancer in Nigeria.
5. Conclusion
The incidence of pancreatic cancer is relatively low in our center. Most patients present
with advanced condition only amenable to palliative measures. Young adult patients are
often seen to be healthier than older ones. Lack of awareness, socio-cultural habits, and
carelessness could be fatal for patients who suffer from pancreatic cancer; therefore,
awareness should be increased among healthcare professionals and mainly among
Third World countries’ citizen. The earlier the diagnosis is made, the better are the
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chances for the patient’s survival. There are still significant challenges in the area of
diagnosis, screening, treatment, and research. The role of public health campaign to
educate the populace on the disease and early presentation cannot be overemphasized.
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